Oral Bioavailability Assessment

Specifically geared to personnel in the pharmaceutical and biotechnology industries, this book describes the basics and challenges of oral bioavailability - one of the most significant hurdles in drug discovery and development.
•    Describes approaches to assess pharmacokinetics and how drug efflux and uptake transporters impact oral bioavailability
•    Helps readers reduce the failure rate of drug candidates when transitioning from the bench to the clinic during development
•    Explains how preclinical animal models - used in preclinical testing - and in vitro tools translate to humans, which is an underappreciated and complicated area of drug development
•    Includes chapters about pharmacokinetic  modelling, the Biopharmaceutics Drug Disposition Classification System (BDDCS), and the Extended Clearance Classification System (ECCS)
•    Has tutorials for applying strategies to medicinal chemistry practices of drug discovery/development

AYMAN F. EL-KATTAN, B. Pharm, PhD, is Associate Research Fellow in Pfizer's Pharmacokinetics, Dynamics, and Metabolism Department, Cambridge Laboratories and an Adjunct Professor at College of Pharmacy-University of Rhode Island in Rhode Island, US. Dr. El-Kattan is a reviewer for several journals and is an active member of the American Association of Pharmaceutical Scientists (AAPS). He serves on the executive committee of the Drug Transporter focus group. He has been invited speaker 50 times at national/international conferences and has published over 100 papers in peer-reviewed Journals, book chapters, and proceedings.